Envista (NYSE:NVST) Price Target Raised to $19.00

Envista (NYSE:NVST) had its price objective boosted by Wells Fargo & Company from $17.00 to $19.00 in a report published on Friday morning,Benzinga reports. The firm currently has an equal weight rating on the stock.

Several other research firms also recently commented on NVST. Bank of America lowered their target price on shares of Envista from $26.00 to $23.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Baird R W raised shares of Envista from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 27th. Morgan Stanley upped their price target on shares of Envista from $16.00 to $17.00 and gave the company an “equal weight” rating in a research note on Friday. UBS Group upped their price target on shares of Envista from $18.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, July 29th. Finally, Robert W. Baird raised shares of Envista from a “neutral” rating to an “outperform” rating and upped their price target for the company from $21.00 to $23.00 in a research note on Tuesday, May 27th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, four have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Envista presently has a consensus rating of “Hold” and an average price target of $20.92.

Envista Stock Performance

NVST opened at $20.78 on Friday. The firm has a market cap of $3.45 billion, a P/E ratio of 64.94, a PEG ratio of 1.22 and a beta of 1.00. Envista has a 1-year low of $14.22 and a 1-year high of $23.00. The company has a 50 day simple moving average of $19.41 and a two-hundred day simple moving average of $18.60. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.44 and a quick ratio of 2.08.

Envista (NYSE:NVST) last released its earnings results on Thursday, July 31st. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.24 by $0.02. Envista had a net margin of 2.11% and a return on equity of 4.84%. The firm had revenue of $682.10 million for the quarter, compared to the consensus estimate of $638.21 million. During the same quarter in the previous year, the firm earned $0.11 earnings per share. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. Equities analysts forecast that Envista will post 1 earnings per share for the current fiscal year.

Institutional Trading of Envista

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. UMB Bank n.a. raised its position in Envista by 214.4% in the 1st quarter. UMB Bank n.a. now owns 2,094 shares of the company’s stock worth $36,000 after purchasing an additional 1,428 shares during the period. Parallel Advisors LLC raised its position in Envista by 100.1% in the 2nd quarter. Parallel Advisors LLC now owns 2,792 shares of the company’s stock worth $55,000 after purchasing an additional 1,397 shares during the period. Palouse Capital Management Inc. raised its position in Envista by 14.4% in the 1st quarter. Palouse Capital Management Inc. now owns 9,444 shares of the company’s stock worth $163,000 after purchasing an additional 1,186 shares during the period. FourThought Financial Partners LLC purchased a new stake in Envista in the 1st quarter worth about $180,000. Finally, Tower Research Capital LLC TRC raised its position in Envista by 51.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,057 shares of the company’s stock worth $213,000 after purchasing an additional 3,751 shares during the period.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.